Fig. 7

USP22 loss sensitizes BC cells to standard therapies and OXPHOS-specific inhibition: A Dose response assay of siControl- and siUSP22-treated MDAMB231 and HCC1954 cells with increasing doses of cisplatin and lapatinib, respectively. B Receiver operating characteristic (ROC) analysis indicates a poor response to standard therapies (left panel) and a high probability of disease recurrence (right panel) in BLBC and HER2⁺-BC patients with high expression of USP22 (source: https://www.rocplot.org/). FPR: False Positive Rate, TPR: True Positive Rate. C A strong synergistic effect was observed in HCC1806 cells treated with increasing doses of USP22i-S02 and cisplatin. D Dose response assay of siControl- and siUSP22-treated MDAMB231 cells with increasing doses of rotenone and oligomycin. Statistics: A-B (left panel): Mann–Whitney test. All dose response experiments were performed in biological triplicates